No Data
No Data
Jefferies Initiates Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Announces Target Price $58
Jefferies Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $58
Tarsus to Participate in Upcoming Investor Conference
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Is Expected To Breakeven In The Near Future
Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Cuts Target Price to $60
Barclays Sticks to Their Buy Rating for Tarsus Pharmaceuticals (TARS)